pharmaphorum17d
The FDA’s Guidance on Labels and Cartons: yet another attack on pharmaceutical trade dress?
Further, the FDA does not provide any evidence to support the presumption that manufacture's name and logo create clutter and impact the readability of pharmaceutical labels and packaging.
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and ...